Relationship Graph Explorer

Follow the connections

Every herb, ingredient, formula, gene target, and disease — connected through real research. Search, pick a subject, and navigate the graph in any direction.

🌿

Herb

→

→

→

→

🧪

Evidence

23,295

trials · metas · refs

Plus 6,743 TCM formulas connecting herbs together

Subject Type: 🌿 Herbs ⚗️ Ingredients 📜 Formulas 🧬 Targets 🏥 Diseases

Quick picks: Taxol Oxytocin Morphine (?)-nicotine Testosterone Melatonin Caffeine L-ascorbic acid Progesterone Coumarins

⚗️ Ingredient

Galanthamine

Open on HERB 2.0 ↗

Clinical Trials

Meta-Analyses

PubMed References

Top Conditions Studied with Galanthamine

Alzheimer's Disease 7 Alzheimer Disease 7 Schizophrenia 5 Alzheimer Disease|Dementia 4 Bipolar Disorder 3 Schizophrenia|Schizoaffective Disorder 2 Dementia|Alzheimer Disease 2 Dementia 2 Healthy 2 Pharmacological interventions used to manage Vascular dement 1 Biomarkers, Pharmacological 1 Smoking|Tobacco Withdrawal 1

📋 Sample Trials

NCT00000172

Evaluation of Galantamine in the Treatment of Alzheimer's Disease

Completed · Phase 3

NCT00035191

A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia

Completed · Phase 3

NCT00035204

A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease

Completed · Phase 4

📊 Sample Meta-Analyses

CRD42017068231

Galantamine for schizophrenia: a systematic review and meta-analysis

Schizophrenia.

CRD42018109231

Donepezil, galantamine, rivastigmine and memantine for Alzheimer's disease: a Bayesian network meta-analysis

Alzheimer's disease.

CRD42022360642

Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, Memantine and sodium oligomannate for the Treatment of Alzheimer’s Disease: A Systematic Review and Meta-Analysis

Alzheimer’s disease(AD) is the most common cause of dementia, affecting more tha

📚 Sample References

PMID 33836162

Neuroprotective role of galantamine with/without physical exercise in experimental autoimmune encephalomyelitis in rats

Life Sci · 2021

PMID 35659521

Enhanced parasympathetic cholinergic activity with galantamine inhibited lipid-induced oxidative stress in obese African Americans

Mol Med · 2022

⚗️ All Ingredient data fields for Galanthamine

⚗️ Identity

Name

Galanthamine

Aliases / Synonyms

Galantamine; 357-70-0; (-)-Galanthamine; Lycoremin; Lycoremine; Jilkon; Galantamina; Galanthaminum; Galantamin

🧪 Chemistry

Molecular Weight

287.3590

LogP

1.8503

Drug-likeness

0.801

H-Bond Acceptors

H-Bond Donors

Rotatable Bonds

🔬 Structures

Canonical SMILES

CN1CCC23C=CC(CC2OC4=C(C=CC(=C34)C1)OC)O

Isomeric SMILES

CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O

InChIKey

ASUTZQLVASHGKV-JDFRZJQESA-N

InChI

InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1

🔗 External References

HERB DB

HBIN027010 ↗

PubChem CID

9651 ↗

NPASS

NPC78359

SymMap

15438

TCMID

8082

TCM-ID

4219

🔍 Raw view — every non-empty column on this row (30 fields)

name

Galanthamine

common names

Galantamine; 357-70-0; (-)-Galanthamine; Lycoremin; Lycoremine; Jilkon; Galantamina; Galanthaminum; Galantamin

herb ingredient id

HBIN027010

canonical smiles

CN1CCC23C=CC(CC2OC4=C(C=CC(=C34)C1)OC)O

isomeric smiles

CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O

inchi

InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1

inchikey

ASUTZQLVASHGKV-JDFRZJQESA-N

mol wt

287.3590

num h acceptors

num h donors

mol logp

1.8503

num rotatable bonds

drug likeness

0.801

symmap mol id

15438

tcmid ingredient id

8082

tcm id ingredient id

4219

pubchem cid

9651

npass id

NPC78359

🏥 Linked Health Topics

12 · studied for these conditions (text bridge)

Cerebrovascular Accident

group

Subarachnoid Hemorrhage

syndrome

Chronic Schizophrenia

📋 Clinical Trials

12 · subject of clinical study

NCT00000172 Evaluation of Galantamine in the Treatment of Alzheimer's Disease

→ Alzheimer Disease

NCT00035191 A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in

→ Dementia, Vascular

NCT00035204 A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Ga

→ Alzheimer Disease

NCT00082602 Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer'

→ Alzheimer's Disease

NCT00161044 An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine i

→ Chronic Schizophrenia

NCT00164242 Treatment of Tardive Dyskinesia With Galantamine

→ Tardive Dyskinesia

NCT00176423 Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia

→ Schizophrenia|Schizoaffective Disorder

NCT00195845 A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dys

→ Bipolar Disorder

NCT00230997 Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies

→ Lewy Body Disease

NCT00252603 Galantamine Versus Placebo in Childhood Autism

→ Autism|Childhood Autism

NCT00299676 An Observational Study of the Safety and Effectiveness of Galantamine in the Tre

→ Alzheimer Disease|Dementia|Galantamine

NCT00301574 An Efficacy and Safety Study of Galantamine for the Treatment of Patients With A

→ Alzheimer Disease

📊 Meta-Analyses

10 · systematic review

CRD42017068231 Galantamine for schizophrenia: a systematic review and meta-analysis

→ Schizophrenia.

CRD42018109231 Donepezil, galantamine, rivastigmine and memantine for Alzheimer's disease:

→ Alzheimer's disease.

CRD42022360642 Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, Memantine and sodiu

→ Alzheimer’s disease(AD) is the most common cause o

CRD42023412516 Efficacy and Safety of Cholinesterase Inhibitors, Memantine, and Sodium Oligoman

→ Alzheimer’s disease(AD) is the most common cause o

CRD42023457210 Evaluating Pharmacological Interventions for Vascular Dementia: A Network Meta-A

→ Pharmacological interventions used to manage Vascu

CRD42023465502 Anticholinesterases for Neuropsychiatric Symptoms among Patients with Parkinson&

→ Parkinson's disease is a complex neurological diso

CRD42023468989 Systematic review and network meta-analysis of predictive validity of streptozoc

CRD42023485395 Cardiovascular outcomes of cholinesterase inhibitors in Parkinson’s disease and

→ Cardiovascular outcomes in trials of cholinesteras

CRD42023493904 Comparing Effectiveness and Safety of cholinesterase inhibitors vs anti-amyloid-

→ Study patients were diagnosed with mild to moderat

CRD42023494082 Cholinesterase inhibitors and cognitive adverse effects of electroconvulsive the

→ Electroconvulsive therapy (ECT) is effective for t

📚 PubMed References

2 · cited research

PMID 33836162 Neuroprotective role of galantamine with/without physical exercise in experiment

Life Sci

PMID 35659521 Enhanced parasympathetic cholinergic activity with galantamine inhibited lipid-i

Mol Med

How relationships are computed

Clinical Trials / Meta-Analyses / References: direct foreign-key link via subject_entity_id (Phase 2d wireup)
Formula ↔ Herbs: text bridge via formulas.herbs_in_pinyin matching herbs.pinyin_name
Herb ↔ Ingredient: empty — needs HERB_herb_ingredient import
Ingredient ↔ Target: empty — needs HERB_ingredient_target import
Target ↔ Disease: empty — needs HERB_target_disease import
Herb → Target → Disease (full chemical spine): awaiting Phase 2e link tables